Cadila Healthcare Limited is associated with researching, producing, developing, marketing and distributing pharmaceutical products in India and several other countries like Spain, South Africa, France as well as Latin American countries. It offers a wide range of products, including wellness products, active pharmaceutical ingredients, human dosage formulations, vaccines, animal healthcare products, and biosimilars.
Apart from this, the company offers several other products in various medical aspects of pain-management, gastrointestinal therapy, gynaecology, dermatology, respiratory issues, etc. Among some of its famous products are, Glucon-D (glucose power, EverYuth in their skincare products range, Sugar-Free and Nycil (prickly heat talc).
Additionally, Cadila has ongoing development of 21 biosimilars along with six different novel products. It also has drugs in multiple aspects for treatment of autoimmune diseases, cancer, diseases concerned with ophthalmology, hepatology, nephrology, rheumatology and several infectious diseases. It also associates itself with retail pharmacy, labour supply along with administration activities. Cadila is an Ahmedabad based company in India and was incorporated back in 1952.
About Company Information:
In 1996, Cadila Healthcare Ltd launched Falcigo through a strategic alliance agreement with a China-based company named Gulin Pharma. In MAY, 2000 Cadila had a helping hand for strengthening its southern market by acquiring Recon Ltd. In the following year, the company acquired German Remedies. This newly acquired company was the top M&A company in the pharmaceutical sector in India.
In the same year, 2001, Cadila entered into an alliance with Oncova with the aim of running research together in the aspect of Oncogenomics. The next year, in 2002, the company went on to acquire Banyan Chemicals. In the following year, in 2003, Zydus Pathline, German Remedies, Zoom Properties and Recon Healthcare, all of them merged with Cadila Healthcare Ltd.
In 2005, Cadila Healthcare Ltd. entered into a strategic agreement with Mallinckrodt Pharmaceuticals Generics. This was a strategic alliance for marketing products launched by Mallinckrodt through one of their business units, under a single joint label.In 2005 itself, the company wished to cater to international needs by manufacturing active pharmaceutical ingredients and cytotoxic drugs along with injectables, for this purpose it signed a fifty-fifty joint agreement with Mayne Pharma, an Australia based company.
During 2005-2006 the company signed an agreement with Bharat Serums and Vaccines Ltd. These two companies came together to form Zydus BSV Pharma Private Limited for developing, manufacturing and marketing proprietary Novel Drug Delivery System that would sell anti-cancer goods in international markets.
During 2007-2008, Cadila launched two new divisions, namely, Fortiza and Corza, while focusing on restructuring their existing Alidac division. In February of 2008, in the aspect of research in drug discovery and their development, Cadila went into a 3-year contract with a Swedish company Karo Bio.
On the 28th of January in 2011, Bayer Healthcare had signed an agreement with Cadila for setting up Bayer Zydus Pharma which will be responsible for selling pharmaceutical products in India. Each of these two companies entering the alliance were to hold 50 of shares each and have equal representation on the board, Bayer Zydus was headquartered in Mumbai.
On 25th of July, 2013, Cadila along with a non-profit organization based in Seattle, named IDRI, declared that these two organizations would collaborate for clinical development of IDRI’s VL vaccine for attacking parasites. It was also agreed upon that Cadila would also be responsible for producing this product.
On the 31st of December, 2015, the company informed that the USFDA sent a letter of warning for the company’s Ahmedabad active pharmaceutical ingredients facility and its Moraiya formulation. In February of 2016, the company informed that it was permitted by the USFDA for marketing Doxycycline Capsules USP, 100 mg, 50 mg, and 75 mg.
On the 28th of March, 2016, Cadila announced that its subsidiary company Zydus was all set to acquire Actibile from a company named Albert David Ltd. This brand of the drug is for gastroenterology aspect and also used for treating stones in the gallbladder.
How Cadila HealthcareLtd, is categorised as a Pharmaceutical and Healthcare Sector, and Pharmaceutical Industry :
The Pharmaceutical Industry includes companies that derive their business by researching, discovering, developing, manufacturing, and marketing and distributing pharmaceutical medicines and drugs.
Cadila Healthcare Ltd is categorized under the Health care sector and Hospitals and Medical services Industry. Healthcare sectors consist of firms involved in the medical space. It is one of the multiple sectors that comprise a range of businesses, including ones that offer medical services directly, or to those that work to develop, create and market medical equipment and medicines. It also includes the other services that provide medical insurance and other related products, and many more.
The stocks of health care companies mostly have mixed performance. It is due to the inherent challenges to the industry each year, regulatory uncertainties, fiscal policy concerns, and more.
Cadila HealthcareLtd, Competitors and Sector Peers:
Aarey Drugs & Pharmaceuticals Ltd. AARDRU
Aayush Food & Herbs Ltd. AAYFOO
ABL Bio-Technologies Ltd. ABLBIO
Addlife Pharma Ltd. ADDPHA
Bafna Pharmaceuticals Ltd. BAFPHA
Bajaj Healthcare Ltd. BAJHEA
Brooks Laboratories Ltd. BROLAB
Dishman Pharmaceuticals & Chemicals Ltd.[Merged] DISPHA
Divi's Laboratories Ltd. DIVIL
Dr. Reddy's Laboratories Ltd. DR
Dujohn Laboratories Ltd. DUJLAB
Earum Pharmaceuticals Ltd.
Elder Health Care Ltd. ELDHEA
Elder Pharmaceuticals Ltd. ELDPHA
Elegant Pharmaceuticals Ltd. ELEPHA
Gennex Laboratories Ltd. GENLAB
Genomics Biotech Ltd. GENBIO
GlaxoSmithKline Pharmaceuticals Ltd. GLAPHA
Glenmark Pharmaceuticals Ltd. GLEPHL
IOL Chemicals and Pharmaceuticals Ltd. IOLCHE
JK Pharmachem Ltd. JKPHAL
Jubilant Life Sciences Ltd. JUBILO
Jupiter Bioscience Ltd. JUPIBI
Novartis India Ltd. NOVAIN
Ortin Laboratories Ltd. ORTLAB
Piramal Enterprises Ltd. NICPIR
Piramal Phytocare Ltd. PIRLIF
Ranbaxy Laboratories Ltd. RANLAB
Sanjivani paranteral Ltd. SANPAR
Sarvodaya Labs Ltd. SARLAB
Sun Pharmaceutical Industries Ltd. SUN28
TTK Healthcare Ltd. TTKHEA
Venmax Drugs & Pharmaceuticals Ltd. YENDRU
Venus Remedies Ltd. VENREM
Zenith Healthcare Ltd. ZENHEA
Zenlabs Ethica Ltd. SHRLAK
Zenotech Laboratories Ltd. ZENLAB
Zim Laboratories Ltd. ZIMLAB
Zora Pharma Ltd.[Amalgamated] ZORPHA
Zota Healthcare Ltd. ZOTHEA
Zydus Cadila gets tentative nod from USFDA to market cancer drugThe Economic TimesNewsBotJul 15 4:46 AM
Cadila arm completes sale of animal health business for Rs 2,921 croreThe Economic TimesNewsBotJul 2 7:36 AM
Zydus Cadila gets USFDA nod to market generic HIV infection treatment tabletsThe Economic TimesNewsBotJun 28 11:36 AM
Covid cases with variants of concern rose from 10% in May to 51% till June 20: Parliamentary panel toldThe Economic TimesNewsBotJun 27 11:16 AM
Zydus Cadila COVID-19 vaccine for children above 12 yrs expected by August, says NTAGI chiefThe Economic TimesNewsBotJun 24 7:46 AM
Zydus Cadila gets tentative USFDA nod to market generic sclerosis treatment drugThe Economic TimesNewsBotJun 23 5:06 AM
India likely to have COVID vaccine for children above 2 years by September-October: AIIMS DirectorThe Economic TimesNewsBotJun 23 4:26 AM
DNA-based coronavirus vaccine: What is it and how does it work?The Economic TimesNewsBotJun 19 1:11 AM
Zydus to seek emergency nod for Covid vaccine soonThe Economic Times